Mark D. Charles
Impact in
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
- Oncology top 10%
- PARP inhibition in cancer therapy
Papers in
- Oncology 4
- PARP inhibition in cancer therapy 3
- Pancreatic and Hepatic Oncology Research 1
-
- Synthesis and biological activity 3
- Synthesis of heterocyclic compounds 1
- Co-authors
- Stephen L. Buchwald (1 shared paper)Stephen Rayport (1 shared paper)Laura Novellasdemunt (1 shared paper)James I. MacRae (1 shared paper)Zena Wilson (1 shared paper)Wei Lin (1 shared paper)Andrés Méndez‐Lucas (1 shared paper)Manuel Rodriguez‐Justo (1 shared paper)
- Journals
- Journal of Medicinal Chemistry (3 papers)Clinical Cancer Research (1 paper)MedChemComm (1 paper)Molecular Cancer Therapeutics (1 paper)Oncotarget (1 paper)
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
Mark D. Charles
12 papers receiving 1k citations
Mark D. Charles's Hit Papers
Peers
Comparison fields: 5 of 60
- Cancer Research 138
- Oncology 203
- Organic Chemistry 293
- Biochemistry 39
- Molecular Biology 358
Countries citing papers authored by Mark D. Charles
This map shows the geographic impact of Mark D. Charles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Charles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Charles more than expected).
Fields of papers citing papers by Mark D. Charles
This network shows the impact of papers produced by Mark D. Charles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Charles. The network helps show where Mark D. Charles may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark D. Charles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance Hit paper breakdown → | 2021 | 286 |
| 2 | 2005 | 236 | |
| 3 | 2010 | 150 | |
| 4 | 2020 | 116 | |
| 5 | 2015 | 42 | |
| 6 | 2010 | 39 | |
| 7 | 2022 | 34 | |
| 8 | 2001 | 33 | |
| 9 | 2017 | 27 | |
| 10 | 2019 | 25 | |
| 11 | 2011 | 23 | |
| 12 | 2015 | 15 | |
| 13 | 2026 | 0 |
About Mark D. Charles
Mark D. Charles is a scholar working on Oncology, Organic Chemistry, Cancer Research, Cell Biology and Biochemistry, having authored 13 papers that have together received 1k indexed citations. Recurring topics across this work include Synthesis and biological activity (3 papers), PARP inhibition in cancer therapy (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Protein Kinase Regulation and GTPase Signaling (2 papers), Synthesis of heterocyclic compounds (1 paper), Microtubule and mitosis dynamics (1 paper), Pancreatic and Hepatic Oncology Research (1 paper) and Cellular transport and secretion (1 paper). The work is most often cited by research in Cancer Research (138 citations), Oncology (203 citations), Organic Chemistry (293 citations), Biochemistry (39 citations) and Molecular Biology (358 citations). Mark D. Charles has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Stephen L. Buchwald, Stephen Rayport, Laura Novellasdemunt, James I. MacRae, Zena Wilson, Wei Lin, Andrés Méndez‐Lucas, Manuel Rodriguez‐Justo, Tony M. Raynham and Mariia O. Yuneva. Their work appears in journals such as Journal of Medicinal Chemistry, Clinical Cancer Research, MedChemComm, Molecular Cancer Therapeutics and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.